Sage Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Sage Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sage Therapeutics Inc Strategy Report
- Understand Sage Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets drugs for the treatment of central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Its flagship product Zulresso (brexanolone) is a proprietary intravenous (IV) formulation administered for the treatment of postpartum depression (PPD). The company also has various pipeline products for the treatment of indications such as major depressive disorders, bipolar depression, Parkinson's disease, insomnia, epileptiform disorders, and NMDA hypofunction. The company operates in the US, Bermuda, Germany, Switzerland, Scotland, England and Wales through its subsidiaries. Sage is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
215 1st St, Cambridge, Massachusetts, 02142-1213
Website
www.sagerx.com
Telephone
1 617 2998380
No of Employees
487
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SAGE (NASD)
Revenue (2022)
$86.5M
1024.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-1.6%
(2022 vs 2021)
Market Cap*
$939.5M
Net Profit Margin (2022)
XYZ
91.0%
(2022 vs 2021)
* As of and is in US$
Sage Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Brexanolone | Patient Advocacy | - |
| Pipeline - | Patient Support | Zulresso |
| Central Nervous System: | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In August, the company and Biogen announced the U.S. Food and Drug Administration approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). |
| 2023 | Regulatory Approval | In February, the company announced the European Medicines Agency (EMA) granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease (HD). |
| 2023 | Regulatory Approval | In February, the company and Biogen announced that the FDA has accepted the submission of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). |
Competitor Comparison
| Key Parameters | Sage Therapeutics Inc | Amgen Inc | Jazz Pharmaceuticals Plc | Supernus Pharmaceuticals Inc | Marinus Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | United States of America | United States of America |
| City | Cambridge | Thousand Oaks | Dublin | Rockville | Radnor |
| State/Province | Massachusetts | California | - | Maryland | Pennsylvania |
| No. of Employees | 487 | 26,700 | 2,800 | 652 | 165 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Geno Germano | Chairman | Executive Board | 2024 | - |
| Barry Greene | Chief Executive Officer; Director | Executive Board | 2020 | 59 |
| Kimi Iguchi | Chief Financial Officer | Senior Management | 2013 | 60 |
| Laura Gault, MD, Ph.D | Chief Medical Officer | Senior Management | 2022 | - |
| Albert Robichaud, Ph.D. | Chief Scientific Officer | Senior Management | 2011 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward